Literature DB >> 16175027

Myocardial dysfunction in meningococcal septic shock.

N Makwana1, P B Baines.   

Abstract

PURPOSE OF REVIEW: The underlying pathophysiology of sepsis has long been disputed. Systemic vasodilatation is important in the development of shock and, in septic critically ill adults who have been volume resuscitated, the systemic pressure is often low and the cardiac output high. In septic children however, and especially in those with meningococcal septic shock, poor cardiac output as a consequence of depressed myocardial function seems to be important, often being the cause of death in these patients. There is much evidence for disturbance of myocardial performance, yet despite the literature, there is still no consensus on how best to manage this complication of meningococcal disease. RECENT
FINDINGS: Many mediators have been proposed as the cause of the reduced myocardial performance, most recently interleukin-6 has emerged as a possible candidate involved in the pathophysiology of the myocardial dysfunction. Cardiac troponin I has been shown to be a marker of myocardial injury and may be used to monitor left ventricular function. Newer treatments emerging to manage the dysfunction include reports of success with phosphodiesterase inhibitors.
SUMMARY: Accepting that myocardial dysfunction may be an important cause of the shock state in overwhelming meningococcal disease, the approach to management may need to be tailored appropriately. Although presently there is no targeted treatment, it may be that therapy focused on inhibiting or antagonising interleukin-6 will be helpful in the future. Regardless of the importance of myocardial depression, fluid resuscitation remains a cornerstone in the management of severe meningococcal disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16175027     DOI: 10.1097/01.ccx.0000176699.51456.13

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  5 in total

Review 1.  Meningococcal disease and its management in children.

Authors:  C Anthony Hart; Alistair P J Thomson
Journal:  BMJ       Date:  2006-09-30

2.  Experimental Evidence of Bacterial Colonization of Human Coronary Microvasculature and Myocardial Tissue during Meningococcemia.

Authors:  Jean Bergounioux; Mathieu Coureuil; Emre Belli; Mohamed Ly; Michelle Cambillau; Nicolas Goudin; Xavier Nassif; Olivier Join-Lambert
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

3.  Caging a Beast in the Inflammation Arena: Use of Chinese Medicinal Herbs to Inhibit a Late Mediator of Lethal Sepsis, HMGB1.

Authors:  Shu Zhu; Wei Li; Jianhua Li; Andrew E Sama; Haichao Wang
Journal:  Int J Clin Exp Med       Date:  2008-01-20

4.  Type IV pilus retraction enables sustained bacteremia and plays a key role in the outcome of meningococcal sepsis in a humanized mouse model.

Authors:  Jean-Philippe Barnier; Daniel Euphrasie; Olivier Join-Lambert; Mathilde Audry; Sophia Schonherr-Hellec; Taliah Schmitt; Sandrine Bourdoulous; Mathieu Coureuil; Xavier Nassif; Mohamed El Behi
Journal:  PLoS Pathog       Date:  2021-02-16       Impact factor: 6.823

5.  Norepinephrine supplemented with dobutamine or epinephrine for the cardiovascular support of patients with septic shock.

Authors:  Khaled M Mahmoud; Amany S Ammar
Journal:  Indian J Crit Care Med       Date:  2012-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.